Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Cash flows from operating activities:
Net loss	$ (11,779)	$ (4,154)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	858	761
Gain from change in fair value of embedded derivatives	(84)	(39)
Depreciation	1,151	963
Interest expense on preferred stock obligation	430	480
Unrealized foreign exchange gains	(845)	(1,513)
Other non-cash transactions, net	203	(125)
Decrease (increase) in operating assets:
Accounts receivable	16,493	3,747
Inventories	5,478	(725)
Project assets	(8,939)	(4,928)
Other assets	120	(2,857)
Increase (decrease) in operating liabilities:
Accounts payable	(1,141)	(468)
Accrued liabilities	9,972	(131)
Deferred revenue	(3,321)	6,718
Net cash provided by (used in) operating activities	8,596	(2,271)
Cash flows from investing activities:
Capital expenditures	(1,314)	(1,616)
Project asset expenditures	(2,044)	0
Net cash used in investing activities	(3,358)	(1,616)
Cash flows from financing activities:
Repayment of debt	(8,916)	(121)
Proceeds from debt	20,102	0
Increase in restricted cash and cash equivalents	(10,387)	(2,144)
Payment of preferred dividends and return of capital	(1,033)	(1,094)
Proceeds from sale of common stock, net of registration fees	13,306	8,488
Net cash provided by financing activities	13,072	5,129
Effects on cash from changes in foreign currency rates	(218)	(288)
Net increase in cash and cash equivalents	18,092	954
Cash and cash equivalents-beginning of period	58,852	83,710
Cash and cash equivalents-end of period	76,944	84,664
Supplemental cash flow disclosures:
Cash interest paid	359	155
Noncash financing and investing activity:
Common stock issued for Employee Stock Purchase Plan in settlement of prior year accrued employee contributions	105	168
Accrued grant awards	1,099	0
Accrued Sale of Common Stock, cash received in subsequent period	$ 475	$ 33